David Kauffmann

AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark.

EEP Advisers Ltd. (EEP) is a private equity firm founded in 1999 by Hans Blomberg and David Kauffmann. The firm is headquartered in London.

PhaseOneTrials A/S is a Danish Contract Research Organization (CRO) that conducts clinical phase I trials and early phase II trials of new drug candidates. Phase I trials include studies in which a new drug is tested for the first time in healthy humans – also known as “First-in-Man” studies. Early phase II studies, or “Proof-of-Concept” studies, include testing a drug in small groups of patients to determine whether the drug has the desired effects on a given disease.

Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark.

AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy.

Bactolife A/S is a Danish industrial biotech company that specializes in developing biological solutions to strengthen the gut microbiome and combat antimicrobial resistance. Bactolife is based in Kongens Lyngby, Denmark and was founded in 2017 by Andreas Hougaard Laustsen, Per Falholt, Mads Laustsen, David Kauffmann, and Sandra Wingaard Thrane. The company has approximately 40 employees and uses its proprietary binding protein technology to select and produce binding proteins that act on toxins without targeting growth or killing bacteria directly. Bactolife is developing and marketing ingredients for various groups, including mothers and children, the elderly, immunodeficient individuals, travelers, deployed individuals, and animal health. The company has proof of concept for its technology, including its most advanced animal health product, ablacto+, which stabilizes the gut of piglets and reduces the severity of post-weaning diarrhea. Mads Laustsen has been the CEO since 2017.